DNLI - Denali Therapeutics Inc.
Chart Events
Engulfing Line (Bullish)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 24.18 |
| Open | 24.10 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 24.08 - 25.31 |
| 52 Week Range | 12.39 - 30.41 |
| Volume | 275,311 |
| Avg. Volume | 514,753 |
| Market Cap | 2.666B |
| Beta (5Y Monthly) | 1.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.21 |
| Earnings Date | Aug 04, 2020 - Aug 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.73 |
Fair Value
Related Research
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Denali Therapeutics Inc. (DNLI)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
- Motley Fool
Sanofi and Denali Halt Clinical Trials of Alzheimer Drug
The companies are shifting their joint efforts from DNL747 to DNL788, which has stronger preclinical data.
- SmarterAnalyst
Denali Drops 7% In After-Market On Halt Of DNL747 Drug Study
Denali Therapeutics Inc. (DNLI) announced that it is pausing clinical studies of DNL747, its neurological drug candidate for the treatment of Alzheimer’s disease and ALS, sending shares down some 7% in after-market trading on Tuesday.The stock dropped almost 7% to $23.95 in late market trading after the biotech company said that the decision was made following results from Phase 1b studies of the small molecule RIPK1 inhibitor DNL747 in Alzheimer's disease and amyotrophic lateral sclerosis (ALS).The study was conducted in partnership with Sanofi (SNYNF) to develop small molecule inhibitors of the RIPK1 enzyme, a new class of potential therapeutic agents for a range of neurological and inflammatory diseases, including ALS.The data demonstrated “emerging evidence that higher levels of target inhibition may be required for maximizing efficacy, and challenges to achieving higher doses imposed by molecule-specific toxicity findings with DNL747”.“Together with our partner Sanofi, we have decided to pause clinical studies with DNL747 and focus our efforts on accelerating development of DNL788, which we believe has superior drug properties and a more rapid path toward proof-of-concept clinical studies in patients in multiple neurological indications," said Denali CEO Ryan Watts.RIPK1, receptor-interacting serine/threonine-protein kinase 1, is a critical signaling protein in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body.Denali reported that data from the completed Phase 1 study with peripherally-restricted RIPK1 inhibitor DNL758 in healthy patients display an encouraging profile, as the molecule appears safe and tolerable at doses tested. Denali partner Sanofi is in charge of the development of DNL758 and is currently planning further clinical studies in multiple indications based on successful Phase 1 data.Investors have been enthusiastic about Denali, pushing shares up 56% so far this year to trade at $25.71 as of Tuesday’s close.Earlier this month, five-star analyst Andrew Fein at H.C. Wainwright reiterated a Buy rating on the stock with a $28 price target, saying that Denali’s blood brain pressure barrier (BBB) transport vehicle platform, which leverages receptor-mediated transcytosis (RMT) as a noninvasive strategy for enhancing brain exposure of biotherapeutics, can present a broad future value driver for the company.Denali scores 5 Buys from Wall Street analysts adding up the Strong Buy consensus for the stock. With an average price target of $27.60, analysts still expect shares to add a moderate 7.3% over the coming 12 months. (See Denali stock analysis on TipRanks).Related News: Sorrento’s COVID-19 Cocktail Could Drive Major Upside, Says Analyst Oxford Biomedica Clinches Manufacturing Deal For AstraZeneca’s Covid-19 Vaccine Global Blood Therapeutics Up On Expanded Use Plans For Sickle Cell Treatment More recent articles from Smarter Analyst: * Aurora Cannabis Leap Frogs Canopy Growth as a Better Investment * Afrezza Could Push MannKind Shares Higher, Says 5-Star Analyst * Shopify Teams Up With Blackberry On Canadian Covid-19 App * Marathon- Speedway Sale Reportedly Back In Play; RBC Says Deal ‘Clear Positive’
- GlobeNewswire
Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi
Denali and Sanofi pause DNL747(a) clinical activities based on the totality of DNL747 data and a superior profile of backup compound DNL788(b)Denali and Sanofi intend to.
- GuruFocus.com
Venture Funding of Drug Startups Down, But Not Out
Fourteen biotechs have gone public in 2020, just three fewer than for the same period last year Continue reading...
- PR Newswire
Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity.
- GlobeNewswire
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with.
- Zacks
What Makes Denali Therapeutics Inc. (DNLI) a New Buy Stock
Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Simply Wall St.
Analyst Estimates: Here's What Brokers Think Of Denali Therapeutics Inc. (NASDAQ:DNLI) After Its First-Quarter Report
Investors in Denali Therapeutics Inc. (NASDAQ:DNLI) had a good week, as its shares rose 9.6% to close at US$23.89...
- Zacks
Denali Therapeutics Inc (DNLI) Reports Q1 Loss, Lags Revenue Estimates
Denali Therapeutics Inc (DNLI) delivered earnings and revenue surprises of 3.51% and -39.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update
SOUTH SAN FRANCISCO, May 07, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross.
- Zacks
Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Denali Therapeutics Inc. (DNLI): Are Hedge Funds Right About This Stock?
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- American City Business Journals
Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays
In the span of eight days last month, CytomX Therapeutics Inc. landed a collaboration with Astellas Pharma and captured a $40 million milestone payment from AbbVie Inc. as it preps for a mid-stage cancer clinical trial. “It’s a challenging time for our industry,” said CytomX President and CEO Sean McCarthy.
- GlobeNewswire
Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic
“In these unprecedented times, our resolve to defeat degeneration is undiminished and our top priority is to ensure the health and safety of our employees, community, partners and clinical trial participants,” said Ryan Watts, Ph.D., CEO. For the ongoing DNL151 Phase 1 and Phase 1b trials, enrollment of additional healthy volunteers and patients at higher doses has been paused due to the COVID-19 pandemic. Denali is analyzing available data from these trials and is on track to select either DNL201 or DNL151 by mid-2020 to progress into Phase 2/3 trials.
- Simply Wall St.
Denali Therapeutics Inc. Just Reported And Analysts Have Been Cutting Their Estimates
It's been a mediocre week for Denali Therapeutics Inc. (NASDAQ:DNLI) shareholders, with the stock dropping 19% to...
- GlobeNewswire
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered.
- GuruFocus.com
3 Stocks That Are Way More Expensive Than Tesla
If you want a stock market bet that’s 74% likely to lose money, try investing in high-flying stock that sells for 100 times revenue or more Continue reading...
- American City Business Journals
Denali Therapeutics chief medical officer sets a cultural standard
Chief Medical Officer and Head of Development Company: Denali Therapeutics HQ: South San Francisco Years at company: 5 Career turning point: Switching from clinical medicine to research and moving into a management role at Genentech Advice: Women need to be very intentional with networking, Ho says. “I always encourage people to not apologize for the things they do outside of work, be proud of them, talk about them at work and incorporate them into your work life balance.” Carole Ho’s wending career path to biotech startup Denali Therapeutics brought big risks — and big rewards. In 2002, she had just finished her residency in neurology at Massachusetts General Hospital and Brigham and Women’s Hospital for Harvard Medical School when she decided to chance it all and move west to work in a lab at Stanford University.
- Zacks
Has Denali Therapeutics (DNLI) Outpaced Other Medical Stocks This Year?
Is (DNLI) Outperforming Other Medical Stocks This Year?
- Zacks
Aimmune's Palforzia Wins FDA Approval for Peanut Allergy
Aimmune's (AIMT) Palforzia is the first medicine to receive an FDA nod for treating patients with peanut allergy. Shares rise in pre-market trading.
- GlobeNewswire
Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 9,000,000.
- Zacks
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
- Zacks
Moving Average Crossover Alert: Denali Therapeutics
Denali Therapeutics Inc. (DNLI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- Zacks
Intercept (ICPT) Concludes Enrollment in Study on NASH Drug
Intercept (ICPT) closes enrollment in late-stage study evaluating obeticholic acid for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis.
